Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure**,***
References (31)
- et al.
Prostaglandin modulation of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium chloride combined with efferent cardiac sympathetic stimulation in dogs
J Am Coll Cardiol
(1990) - et al.
Vasodilator therapy with a new stable prostacyclin analog, OP-41483, for congestive heart failure due to coronary artery disease and comparison of hemodynamic effects and platelet aggregation with nitroprusside
Am J Cardiol
(1986) - et al.
The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs
Prostaglandins, Leukot Essent Fatty Acids
(1991) - et al.
Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents
Am Heart J
(1991) - et al.
Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure
Am J Cardiol
(1984) - et al.
Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease
J Am Coll Cardiol
(1983) - et al.
Effects of a prostacyclin analog iloprost on kidney function, renin-angiotensin and kallikrein-kinin systems, prostanoids and catecholamines in man
Prostaglandins
(1985) - et al.
Prostacyclin therapy in patients with congestive heart failure
Am J Cardiol
(1982) - et al.
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
Nature
(1976) - et al.
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides
Prostaglandins
(1976)
Hemodynamic responses to prostacyclin (PGI2) in the conscious sheep
Jpn Circ J
The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients
N Engl J Med
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial
Ann Intern Med
Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia
N Engl J Med
Multicenter randomized trial of epoprostenol in patients with severe heart failure. (Abstr)
J Am Coll Cardiol
Cited by (21)
Prostanoid-mediated inotropic responses are attenuated in failing human and rat ventricular myocardium
2012, European Journal of PharmacologyCitation Excerpt :Prostanoids have been thought to be beneficial in heart failure. Epoprostenol (PGI2) is known to reduce pulmonary and peripheral vascular resistance (Patterson et al., 1995) and clinical studies with short term treatment with epoprostenol in patients with heart failure demonstrated an improvement in exercise tolerance (Sueta et al., 1995). But despite favorable acute and long-term hemodynamic effects (Haywood et al., 1995), long-term treatment of heart failure patients with epoprostenol was prematurely terminated due to increased mortality (Califf et al., 1997).
Emerging medical therapies for pulmonary arterial hypertension
2002, Progress in Cardiovascular DiseasesInternational differences in treatment effects in cardiovascular clinical trials
2001, American Heart JournalCitation Excerpt :Epoprostenol has a variety of properties that suggested it might be of benefit in patients with severe heart failure. It reduces pulmonary vascular and peripheral vascular resistance7 and inhibits platelet aggregation.8 However, FIRST was terminated early because a strong trend toward decreased survival was observed in patients treated with epoprostenol.4
Medical therapy of pulmonary hypertension: The prostacyclins
2001, Clinics in Chest MedicineCitation Excerpt :In this case, all the problems linked to a permanent central venous line, such as infections, are avoided and the management of the system is much simpler. In a preliminary acute study of 12 patients with severe congestive heart failure, intravenous UT-15 induced hemodynamic changes similar to those of epoprostenol.50 A comparison of intravenous UT-15 and epoprostenol was completed in 14 patients with NYHA class III or IV PPH and the results confirmed the comparability of the acute hemodynamic effects of the two compounds (unpublished data).
Prostacyclin (PGI<inf>2</inf>) scaffolds in medicinal chemistry: current and emerging drugs
2022, Medicinal Chemistry Research
- **
See Appendix for a list of the participating centers and investigators.
- ***
This study was supported by a grant from Burroughs Wellcome Co., Research Triangle Park, North Carolina.